GZBL
0024244.600.88% ( +0.04 )
GZBL (002424)
Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates throug...
- Open
- 4.56
- High
- 4.63
- Low
- 4.52
- Prev. Close
- 4.56
- Volume
- 54.54K
- Turnover
- 24.99M
- Avg Price
- 4.58
- Bid/Ask Ratio
- --
- Amplitude
- 2.41%
- 52wk High
- 6.94
- Volume Ratio
- 0.61
- Turnover Ratio
- 0.39%
GZBL Analyst Rating
View MoreForecast & Rating
Aug 25, 2023Price forecast
¥9.92115.65%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Wallstreetcn · Apr 8 at 08:57 AM
Rokid Founder Mingo Zhu Responds: Company Restructuring and Joint-Stock Reform Proceeding at Normal Pace
- Zhitong · Oct 24, 2025 at 06:03 AM
GZBL: Net profit for the third quarter was 4.9798 million yuan, a year-on-year increase of 559.90%
- Zhitong · Oct 15, 2025 at 08:59 PM
The concept of innovative drugs continues to rebound, with GZBL and Luoxin Pharmaceutical both hitting the daily limit
- Zhitong · Oct 15, 2025 at 08:45 PM
The traditional Chinese medicine sector fluctuated and surged, with GZBL hitting the limit up
- Zhitong · Oct 15, 2025 at 04:34 AM
GZBL: The clinical trial application for Tangning Tongluo tablets has been approved
- Zhitong · Aug 19, 2025 at 07:13 AM
GZBL: The capacity expansion and technological transformation project has been completed and put into production, increasing the processing capacity of traditional Chinese medicinal materials to 60,000 tons per year
